首頁 > 市場調查報告書 > 製藥 > 癌症 > 大腸癌、前立腺癌、血管增生分析

聯絡我們?

市場調查報告書

大腸癌、前立腺癌、血管增生分析

Triple Analysis: Colorectal Cancer, Prostate Cancer and Angiogenesis

出版商	BioSeeker Group AB
出版日期	2012年01月	商品編碼	177462
內容資訊	英文 3598 Pages
價格	US $ 5175 PDF by E-mail

簡介
目錄
相關商品

大腸癌、前立腺癌、血管增生分析 是由出版商BioSeeker Group AB在2012年01月所出版的。這份英文市場調查報告書包含3598 Pages 價格從美金5175起跳。

簡介

本報告針對大腸癌、前立腺癌的藥物目標策略、血管增生機制、目的、影響分類為焦點，提供各藥劑目的策略、複合策略競爭基準、臨床實驗與分析計劃，目錄介紹如下。

第1章大腸癌

本報告範圍
以最佳治療結果與投資回收率為前提的大腸癌治療目標
新藥登場：開發階段分類大腸癌藥物目標策略
使用中的複合策略：複合策略分類競爭基準
臨床實驗與分析計劃
免責事項
藥物索引
企業索引
圖表

第2章前立腺癌

本報告範圍
以最佳治療結果與投資回收率為前提的治療目標
新藥登場：開發階段分類前立腺癌藥物目標策略
使用中的複合策略：複合策略分類競爭基準
臨床實驗與分析計劃
藥物索引
企業索引
圖表

第3章血管增生

本報告範圍
以最佳治療結果與投資回收率為前提的治療目標
新藥登場：開發階段分類血管增生藥物目標策略
使用中的複合策略：複合策略分類競爭基準
藥物影響與血管增生的適應癌症
臨床實驗與分析計劃
免責事項
藥物索引
企業索引
圖表

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Key Topics Covered:

Part I: Colorectal Cancer

5.1. The Scope of this Report
6. Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies)
9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies)
10. Disclaimer
11. Drug Index
12. Company Index

Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Prostate Cancer

5.1. The Scope of this Report
6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound Strategies)
9. Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198 Investigators)
11. Drug Index
12. Company Index

Figures: Includes 6 Figures
Tables: Includes 257 Tables
Total Number of Pages: 838

Part III: Angiogenesis

5.1. The Scope of this Report
6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
9. Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications)
10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators)
10. Disclaimer
11. Drug Index
12. Company Index

Figures: Includes 7 Figures
Tables: Includes 300 Tables
Total Number of Pages: 1227

Featured Companies:

This Report Includes the Following Companies:

Abbott
Abraxis BioScience
Acceleron Pharma
Access
ACT Biotech
Active Biotech
Adherex
Advanced Cancer Therapeutics
Advantagene
Advaxis
Advenchen
AEgera
Aeterna Zentaris
Affimed Therapeutics
Agennix
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anavex Life Sciences
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Apthera
Arana Therapeutics
Archer Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Betapharma
BioAlliance Pharma
BioAxone
Biocompatibles
Biogen Idec
BioNumerik
Biostar
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Cadila
Can-Fite BioPharma
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Genesys
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
Clavis Pharma
Cosmo Pharmaceuticals
Cue Biotech
CuraGen
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Dongkook Pharm
Dyax
Dynavax Technologies
ECI
EGEN Inc
Eisai
Elan
Eli Lilly
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Etubics
Exelixis
ExonHit Therapeutics
Facet Biotech
FasTrack Pharmaceuticals
Five Prime Therapeutics
GammaCan
Generex
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gloucester Pharmaceuticals
GlycoGenesys
Got-a-Gene
Gradalis
Green Cross
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IkerChem
ImClone Systems
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAI Pharmaceuticals
Karus Therapeutics
Kiadis
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Labopharm
LEAD Therapeutics
Lee' s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
Meda
Medarex
MediGene
MedImmune
Mediolanum
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mojave Therapeutics
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
NeoPharm
Nerviano Medical Sciences
NewSouth Innovations
NicOx
Nippon Kayaku
Northwest Biotherapeutics
Novartis
Novelix
Novogen
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmaclon
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Plexxikon
POZEN
Pro-Pharmaceuticals
Progen
Progenics Pharmaceuticals
ProStrakan
Protein Sciences
Protherics
Protox Therapeutics
PTC Therapeutics
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Samyang
Sanofi-Aventis
Santaris Pharma
Sareum
Scancell
SciClone Pharmaceuticals
Semafore Pharmaceuticals
Shire
Sigma-Tau
Simcere Pharmaceuticals
Spear Therapeutics
Spirogen
SRI International
SuperGen
Supratek Pharma
Switch Pharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Telik
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
United Biomedical
Vaxon Biotech
VBL Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroTarg
Wyeth
Xerion
Xoma
Yakult Honsha

YM BioSciences

Featured Drugs:

A Shortlist of Drugs Included are:

abarelix
abiraterone acetate
aflibercept
Angiozyme
apatinib
ARQ-197
axitinib
bevacizumab
BIBF-1120
bicalutamide
brivanib alaninate
buserelin
capecitabine
catumaxomab
cediranib
celecoxib
cetuximab
cilengitide
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
docetaxel
doxifluridine
dutasteride
endostatin
enzastaurin hydrochloride
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
flutamide
fosbretabulin tromethamine
goserelin
HBP-347
histrelin
INGN-241
interferon gamma
ipilimumab
irinotecan bead
irinotecan hydrochloride
leuprolide
linifanib
MDV-3100
MGN-1703
midostaurin
motesanib diphosphate
nadroparin
nilutamide
OTS-102
panitumumab
patupilone
pazopanib hydrochloride
perifosine
raltitrexed
ramucirumab
regorafenib
ridaforolimus
sorafenib tosylate
sunitinib malate
talactoferrin alfa
tegafur + uracil
tegafur + uracil + leucovorin
thymalfasin
tipifarnib
toremifene citrate
triptorelin
triptorelin pamoate
TS-1
vandetanib
XL-184

zibotentan

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

大腸癌、前立腺癌、血管增生分析

Triple Analysis: Colorectal Cancer, Prostate Cancer and Angiogenesis